BMO Capital Downgrades Vitae Pharmaceuticals (VTAE) to Market Perform
- Nasdaq hits record; bank earnings validate Wall St. rally
- Intrawest Resorts (SNOW) Exploring a Possible Sale - Reuters
- Alibaba (BABA) Has No Plans to Acquire Rest of Groupon (GRPN) - Source
- Time (TIME) Said to Soon Begin Discussions with Interested Buyers - Bloomberg
- JPMorgan (JPM) Reports Q4 EPS of $1.71
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
BMO Capital downgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Outperform to Market Perform with a price target of $21.00 (from $17.00).
Shares of Vitae Pharmaceuticals closed at $20.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Downgrades WABCO Holdings (WBC) to Market Perform
- BMO Capital Downgrades Apartment Investment Management (AIV) to Market Perform
- Impax (IPXL): CVS Generic EpiPen Opportunity Modest Considering Uncertainties - BMO
Create E-mail Alert Related CategoriesDowngrades
Related EntitiesBMO Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!